Neurofibromatosis Therapeutic Acceleration Program (NTAP) is launching a new research program focused on understanding the pathogenesis of cutaneous neurofibromas. NTAP is a philanthropic research entity based at Johns Hopkins University dedicated to the discovery of therapeutics for the peripheral nerve tumors that afflict people with neurofibromatosis type 1 (NF1). Cutaneous neurofibromas represent a major unmet need for NF1 patients. This research program sets the blueprint for improving therapeutics for these tumors by encouraging research proposals that improve the Understanding of Cutaneous Neurofibromas.
Download the request for application announcement here, which includes detailed application instructions.
The submission deadline for the ‘letter of intent’ is May 12, 2017. Applicants will be notified by May 31, 2017 if they are invited to submit a full proposal.
Please direct all questions to Dr. Sharad Verma (email@example.com)